X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2361) 2361
Publication (217) 217
Book Review (62) 62
Book Chapter (33) 33
Dissertation (5) 5
Conference Proceeding (4) 4
Book / eBook (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1747) 1747
index medicus (1059) 1059
male (924) 924
female (827) 827
lipid-lowering therapy (741) 741
middle aged (729) 729
statins (688) 688
aged (614) 614
cardiac & cardiovascular systems (559) 559
risk factors (541) 541
pharmacology & pharmacy (531) 531
cholesterol (522) 522
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (511) 511
lipid-lowering drugs (406) 406
hypolipidemic agents - therapeutic use (395) 395
atherosclerosis (386) 386
coronary-heart-disease (385) 385
adult (375) 375
treatment outcome (361) 361
lipid-lowering treatment (337) 337
prevention (323) 323
peripheral vascular disease (303) 303
cardiovascular disease (297) 297
animals (284) 284
cholesterol, ldl - blood (281) 281
risk (278) 278
atorvastatin (269) 269
medicine, general & internal (266) 266
hypertension (260) 260
myocardial-infarction (260) 260
lipids (256) 256
anticholesteremic agents - therapeutic use (254) 254
hypercholesterolemia (237) 237
coronary heart disease (230) 230
simvastatin (227) 227
drug therapy (225) 225
mortality (219) 219
antihypertensive agents - therapeutic use (218) 218
cardiovascular agents (214) 214
hypertension - drug therapy (214) 214
cardiovascular (213) 213
hypercholesterolemia - drug therapy (209) 209
pravastatin (202) 202
cardiovascular-disease (201) 201
cardiovascular diseases - prevention & control (194) 194
hyperlipidemias - drug therapy (192) 192
care and treatment (185) 185
diabetes (183) 183
low density lipoproteins (181) 181
analysis (178) 178
medicine & public health (173) 173
randomized controlled-trial (172) 172
anticholesteremic agents (170) 170
cardiology (170) 170
cardiovascular diseases (166) 166
statin (166) 166
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (165) 165
research (164) 164
statin therapy (163) 163
secondary prevention (158) 158
disease (157) 157
aged, 80 and over (153) 153
c-reactive protein (153) 153
therapy (152) 152
density-lipoprotein cholesterol (151) 151
health aspects (151) 151
lipids - blood (151) 151
cholesterol - blood (150) 150
randomized controlled trials as topic (150) 150
drug therapy, combination (146) 146
heart-disease (146) 146
internal medicine (144) 144
lipid-lowering agents (140) 140
coronary-artery-disease (139) 139
follow-up studies (139) 139
retrospective studies (136) 136
blood-pressure (134) 134
dyslipidemia (134) 134
time factors (132) 132
acute myocardial-infarction (124) 124
coa reductase inhibitors (124) 124
dyslipidemias - drug therapy (122) 122
prospective studies (120) 120
risk assessment (119) 119
lipid lowering (118) 118
endocrinology & metabolism (117) 117
low-density-lipoprotein (117) 117
primary prevention (117) 117
risk-factors (117) 117
events (116) 116
abridged index medicus (114) 114
cardiovascular events (113) 113
clinical trials as topic (113) 113
biochemistry & molecular biology (111) 111
double-blind (110) 110
article (109) 109
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (108) 108
clinical trials (107) 107
ezetimibe (107) 107
practice guidelines as topic (107) 107
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2340) 2340
Spanish (23) 23
German (20) 20
Japanese (19) 19
French (12) 12
Russian (8) 8
Chinese (3) 3
Italian (2) 2
Korean (2) 2
Portuguese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 11/2013, Volume 15, Issue 11, pp. 1040 - 1048
Aims Postprandial triglyceridaemia is a risk factor for cardiovascular disease (CVD). This study investigated the effects of steady‐state liraglutide 1.8 mg... 
antidiabetic drug | lipid‐lowering therapy | GLP‐1 analogue | phase I‐II study | type II diabetes | randomized trial | Type II diabetes | Randomized trial | Antidiabetic drug | Lipid-lowering therapy | GLP-1 analogue | Phase I-II study | LIPEMIA | SAFETY | RECEPTOR AGONISTS | EXENATIDE | SITAGLIPTIN | INSULIN | lipid-lowering therapy | phase I-II study | THERAPY | GLUCOSE | ENDOCRINOLOGY & METABOLISM | DYSLIPIDEMIA | GLUCAGON | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Diet, High-Fat - adverse effects | Half-Life | Glucagon-Like Peptide 1 - blood | Male | Hypoglycemic Agents - blood | Cardiovascular Diseases - complications | Hypolipidemic Agents - blood | Lipids - blood | Postprandial Period | Cardiovascular Diseases - epidemiology | Female | Glucagon-Like Peptide 1 - pharmacokinetics | Diabetes Mellitus, Type 2 - complications | Hyperlipidemias - complications | Body Mass Index | Hypoglycemic Agents - therapeutic use | Hypolipidemic Agents - adverse effects | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Glucagon-Like Peptide 1 - analogs & derivatives | Obesity - complications | Risk Factors | Hyperlipidemias - prevention & control | Germany - epidemiology | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Gastric Emptying - drug effects | Hyperlipidemias - etiology | Denmark - epidemiology | Aged | Hypolipidemic Agents - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypolipidemic Agents - pharmacokinetics | Hypoglycemic Agents - adverse effects | Liraglutide | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Low density lipoproteins | Anticholesteremic agents | Clinical trials | Triglycerides | Glucose | Fatty acids | Cholesterol | Dextrose | Glucose metabolism | Hypoglycemic agents | Diabetes therapy | Lipids | Diet | Apolipoproteins
Journal Article
Circulation, ISSN 0009-7322, 11/2016, Volume 134, Issue 21, pp. e468 - e495
Journal Article
Journal of Cardiovascular Pharmacology and Therapeutics, ISSN 1074-2484, 9/2013, Volume 18, Issue 5, pp. 401 - 411
Journal Article